



Application Form for Gavi NVS support

Submitted by

**The Government of Democratic People's Republic of
Korea**

for

Measles-rubella 1st and 2nd dose routine, with catch-up campaign

Gavi terms and conditions

1.2.1 Gavi terms and conditions

The terms and conditions of the Partnership Framework Agreement (PFA) between Gavi and the Country, including those provisions regarding anti-corruption and anti-terrorism and money laundering, remain in full effect and shall apply to any and all Gavi support made pursuant to this application. The terms and conditions below do not create additional obligations or supersede those of the PFA. In the event the Country has not yet executed a PFA, the terms and conditions of this application shall apply to any and all Gavi support made pursuant to this application.

GAVI GRANT APPLICATION TERMS AND CONDITIONS

FUNDING USED SOLELY FOR APPROVED PROGRAMMES

The applicant country ("Country") confirms that all funding provided by Gavi will be used and applied for the sole purpose of fulfilling the programme(s) described in the Country's application. Any significant change from the approved programme(s) must be reviewed and approved in advance by Gavi. All funding decisions for the application are made at the discretion of Gavi and are subject to IRC processes and the availability of funds.

AMENDMENT TO THE APPLICATION

The Country will notify Gavi in its Joint Appraisal, or in any other agreed annual reporting mechanism, if it wishes to propose any change to the programme(s) description in its application. Gavi will document any change approved by Gavi according with its guidelines, and the Country's application will be amended.

RETURN OF FUNDS

The Country agrees to reimburse to Gavi all funding amounts that Gavi determines not to have been used for the programme(s) described in its application. The Country's reimbursement must be in US dollars and be provided, unless otherwise decided by Gavi, within sixty (60) days after the Country receives Gavi's request for a reimbursement and be paid to the account or accounts as directed by Gavi.

SUSPENSION/ TERMINATION

Gavi may suspend all or part of its funding to the Country if it has reason to suspect that funds have been used for purpose other than for the programme(s) described in the Country's application, or any Gavi-approved amendment to the application. Gavi retains the right to terminate its support to the Country for the programme(s) described in its application if a misuse of Gavi funds is confirmed.

NO LIABILITY

The Country shall be solely responsible for any liability that may arise in connection with: (i) the implementation of any programme(s) in the Country; and (ii) the use or distribution of vaccines and related supplies after title to such supplies has passed to the Country.

Neither party shall be responsible for any defect in vaccines and related supplies, which remain the responsibility of the relevant manufacturer. Gavi shall not be responsible for providing any additional funding to replace any vaccines and related supplies that are, or became, defective or disqualified for whatever reason.

INSURANCE

Unless otherwise agreed with Gavi, the Country shall maintain, where available at a reasonable cost, all risk property insurance on the Programme assets (including vaccines and vaccine related supplies) and comprehensive general liability insurance with financially sound and reputable insurance companies. The insurance coverage will be consistent with that held by similar entities engaged in comparable activities.

ANTI-CORRUPTION

The Country confirms that funds provided by Gavi shall not be offered by the Country to any third person, nor will the Country seek in connection with its application any gift, payment or benefit directly or indirectly that could be construed as an illegal or corrupt practice.

ANTI-TERRORISM AND MONEY LAUNDERING

The Country confirms that funds provided by Gavi shall not be used to support or promote violence, war or the suppression of the general populace of any country, aid terrorists or their activities, conduct money laundering or fund organisations or individuals associated with terrorism or that are involved in money-laundering activities; or to pay or import goods, if such payment or import, to the Country's knowledge or belief, is prohibited by the United Nations Security Council.

AUDITS AND RECORDS

The Country will conduct annual financial audits, and share these with Gavi, as requested. Gavi reserves the right, on its own or through an agent, to perform audits or other financial management assessment to ensure the accountability of funds disbursed to the Country. The Country will maintain accurate accounting records documenting how Gavi funds are used. The Country will maintain its accounting records in accordance with its government-approved accounting standards for at least three years after the date of last disbursement of Gavi funds. If there is any claims of misuse of funds, Country will maintain such records until the audit findings are final. The Country agrees not to assert any documentary privilege against Gavi in connection with any audit.

CONFIRMATION OF LEGAL VALIDITY

The Country and the signatories for the Country confirm that its application, or any other agreed annual reporting mechanism, is accurate and correct and forms legally binding obligations on the Country, under the Country's law, to perform the programme(s) described in its application, as amended, if applicable.

COMPLIANCE WITH GAVI POLICIES

The Country confirms that it is familiar with all Gavi policies, guidelines and processes relevant to the programme(s), including without limitation the Transparency and Accountability Policy (TAP) and complies with the requirements therein. All programme related policies, guidelines and processes are available on Gavi's official website and/or sent to the Country.

USE OF COMMERCIAL BANK ACCOUNTS

The Country is responsible for undertaking the necessary due diligence on all commercial banks used to manage Gavi cash-based support. The Country confirms that it will take all responsibility for replenishing Gavi cash support lost due to bank insolvency, fraud or any other unforeseen event.

ARBITRATION

Any dispute between the Country and Gavi arising out of or relating to its application that is not settled amicably within a reasonable period of time, will be submitted to arbitration at the

request of either Gavi or the Country. The arbitration will be conducted in accordance with the then-current UNCITRAL Arbitration Rules. The parties agree to be bound by the arbitration award, as the final adjudication of any such dispute. The place of arbitration will be Geneva, Switzerland. The languages of the arbitration will be English or French.

For any dispute for which the amount at issue is US\$ 100,000 or less, there will be one arbitrator appointed by Gavi. For any dispute for which the amount at issue is greater than US \$100,000 there will be three arbitrators appointed as follows: Gavi and the Country will each appoint one arbitrator, and the two arbitrators so appointed will jointly appoint a third arbitrator who shall be the chairperson.

Gavi will not be liable to the country for any claim or loss relating to the programme(s) described in the application, including without limitation, any financial loss, reliance claims, any harm to property, or personal injury or death. The Country is solely responsible for all aspects of managing and implementing the programme(s) described in its application.

Gavi Guidelines and other helpful downloads

1.3.1 Guidelines and documents for download

Please refer to the relevant guidelines concerning your request for support.

Please ensure to consult and download all documents. It is important to note that some documents must be completed offline, and will need to be uploaded in the final steps of your application.

This application form is designed to collect information needed by Gavi to process requests for support, plan procurement of vaccines, plan technical assistance, track data for future reporting, and more.

A key component of the application is a solid operational plan (New Vaccine Introduction Plan for routine support, or Plan of Action for campaign support), explaining how the country will introduce the vaccine or conduct the envisaged campaign, with a corresponding budget. The New Vaccine Introduction Plan or Plan of Action must be submitted together with this application form and will be considered as the foundation of the support request.

For more information on the documents to submit with your application and what they should contain, please refer to the appropriate guidelines: <http://www.gavi.org/support/process/apply/>

Review and update country information

Country profile

2.1.1 Country profile

Eligibility for Gavi support

Eligible

Co-financing group

Initial self-financing

Date of Partnership Framework Agreement with Gavi

7 June 2013

Country tier in Gavi's Partnership Engagement Framework

3

Date of Programme Capacity Assessment

No Response

2.1.2 Country health and immunisation data

Please provide the following information on the country's health and immunisation budget and expenditure.

What was the total Government expenditure (US\$) in 2016?

No Response

What was the total health expenditure (US\$) in 2016?

No Response

What was the total Immunisation expenditure (US\$) in 2016?

No Response

Please indicate your immunisation budget (US\$) for 2016.

No Response

Please indicate your immunisation budget (US\$) for 2017 (and 2018 if available).

12,811,961

2.1.3 National health planning and budgeting cycle, and national planning cycle for immunisation:

The government planning cycle starts on the

1 January

The current National Health Sector Plan (NHSP) is

From

2016

To

2020

Your current Comprehensive Multi-Year Plan (cMYP) period is

2016-2020

Is the cMYP we have in our record still current?

Yes

No

If you selected "No", please specify the new cMYP period, and upload the new cMYP in country documents section.

From

To

If any of the above information is not correct, please provide additional/corrected information or other comments here:

NA

2.1.4 National customs regulations

Please describe local customs regulations, requirements for pre-delivery inspection, and special documentation requirements that are instrumental for the delivery of the vaccine.

The WHO prequalified vaccines do not require licensing, special documentation or pre-delivery inspection.

2.1.5 National Regulatory Agency

Please provide information on the National Regulatory Agency in the country, including status (e.g. whether it is WHO-certified). Please mention a point of contact with phone number and e-mail address. UNICEF will support the process and may need to communicate licensing requirements to the vaccine manufacturers where relevant.

There is a National Regulatory Authority which has so far not been subject to external assessment . It needs to be benchmarked as per WHO standards. Thus NRA is not WHO-certified currently.
Point of Contact : WHO and UNICEF EPI focal points.

National Immunisation Programmes

2.2.2 Financial Overview of Active Vaccine Programmes

IPV Routine

	2018	2019	2020	2021	2022
Country Co-financing (US\$)					
Gavi support (US\$)	754,000	819,568	819,568	819,307	818,089

Pentavalent Routine

	2018	2019	2020	2021	2022
Country Co-financing (US\$)	231,978	235,143	235,143	231,813	231,342
Gavi support (US\$)	1,122,000	1,102,500	1,102,500	1,077,305	1,075,115

Summary of active Vaccine Programmes

	2018	2019	2020	2021	2022
Total country co-financing (US\$)	231,978	235,143	235,143	231,813	231,342
Total Gavi support (US\$)	1,876,000	1,922,068	1,922,068	1,896,612	1,893,204
Total value (US\$) (Gavi + Country co-financing)	2,107,978	2,157,211	2,157,211	2,128,425	2,124,546

Coverage and Equity

2.3.1 Coverage and equity situation analysis

Note: If a recent analysis of the coverage and equity analysis is already available, for example as part of a Joint Appraisal report, you may simply reference the report and section where this information can be found.

Describe national and sub-national evidence on the coverage and equity of immunisation in the country and constraints to improvement. In particular, identify the areas and groups of low coverage or high inequity linked to geographic, socioeconomic, cultural or female literacy considerations, as well as systematically marginalized communities. Specify both the areas and/or populations with low coverage (%) and those with the largest absolute numbers of un-/under-vaccinated children. Among data sources, consider administrative data, coverage surveys, DHS/MCS, equity analyses, Knowledge-Attitude-Practice surveys, and patterns of diseases like measles.

Describe the challenges underlying the performance of the immunisation system, such as:

- o Health work force: availability and distribution;
- o Supply chain readiness;
- o Gender-related barriers: any specific issues related to access by women to the health system;
- o Data quality and availability;
- o Demand generation / demand for immunisation services, immunisation schedules, etc;
- o Leadership, management and coordination: such as key bottlenecks associated with the management of the immunisation programme, the performance of the national/ regional EPI teams, management and supervision of immunisation services, or broader sectoral governance issues;
- o Financing issues related to the immunisation programme that impact the ability to increase coverage, including bottlenecks related to planning, budgeting, disbursement and execution of resources;
- o Other critical aspects: any other aspect identified, for example based on the cMYP, EPI review, PIE, EVM or other country plans, or key findings from available independent evaluations reports.

Describe lessons learned and best practices on the effectiveness of implemented activities to improve coverage and equity; recommendations on changes or new interventions that might be required to accelerate progress (include data to support any findings or recommendations).

Please refer to section 3.1 in the JA for 2017. Briefly, the administrative coverage for all the vaccines is above 95% with interprovincial variation of less than 2% and drop-out rates of less than 1.5%. there is no gender related variance in coverage at all levels.

Challenges:

- > Rapid turnover of the immunization workforce with resultant need of more frequent capacity building activities.
- > The buildings of medical warehouses (especially dry storage) need improvement.
- > Data quality issues - no systematic planning and lack of capacity on internal and external data quality assessment
- > The population is a passive recipient of the services, thus there are no demand related

issues. However, vaccine hesitancy for the successive doses of Pentavalent and MCV pose a minor challenge (drop-out rates less than 5%)

> High donor dependency further aggravated by un-predictable long term availability of financial resources, especially for vaccine procurement.

> NRA is not benchmarked, NCL needs up-gradation with replacement of obsolete equipment. Some vaccines are locally manufactured(JE) and GMP standards need assessment

Lessons Learned and Best Practices:

Please refer to PIE(2016) report in the archives of this portal. Lessons learned, best practices and areas and challenges have been comprehensively describe in the National new vaccine introduction plan for MR uploaded to this portal as a mandatory requirement for Gavi application.




Country documents

2.4.1 Upload country documents

Please provide **country documents** that are relevant for the national immunisation programme and for multiple vaccines, to be taken into account in the review of your application. If you have already provided one or more of these country documents, you do not need to upload it/them again unless the document version changed. If documents cannot be provided, please use the comment functionality to explain why, or by when they will be available.

Note that only general country documents are uploaded here; at the end of section 3 (sub-section “Upload new application documents”) you will be required to provide those documents that are specific to the support requested (for example the new vaccine introduction plan and/or campaign plan of action, new budget, application endorsements etc.)

Country and planning documents

	Country strategic multi-year plan Comprehensive Multi-Year Plan for Immunisation (cMYP) or equivalent country strategic plan	cMYP MoPH DPRK PT 252017_18-04-18_16.03.58.docx
	Country strategic multi-year plan / cMYP costing tool	CMYP E_18-04-18_16.05.06.xls
		DPRK EVM assessment report F_16-03-18_14.37.44.doc

	Effective Vaccine Management (EVM) assessment	
✓	Effective Vaccine Management (EVM): most recent improvement plan progress report	EVM IP tracking sheet F_18-04-18_16.08.50.xlsx
✓	Data quality and survey documents: Final report from most recent survey containing immunisation coverage indicators	CES report 2017.09.11_18-04-18_16.09.56.docx
✓	Data quality and survey documents: Immunisation data quality improvement plan	DQA plan 2018 for Ministry of Public Health DPR Korea_20-04-18_16.30.04.pdf
	Data quality and survey documents: Report from most recent desk review of immunisation data quality	No file uploaded
✓	Data quality and survey documents: Report from most recent in-depth data quality evaluation including immunisation	DQA technical report 2017_20-04-18_16.31.39.pdf
✓	Human Resources pay scale If support to the payment of salaries, salary top ups, incentives and other allowances is requested	Salaries Scale_19-04-18_18.12.51.xlsx

Coordination and advisory groups documents

✓	National Coordination Forum Terms of Reference	Interagency Coordination Committee DPRK_18-04-18_16.13.03.docx
	ICC, HSCC or equivalent	
✓	National Coordination Forum meeting minutes of the past 12 months	ICC MR introduction in DPRK immunization programme 2018_19-04-18_19.12.36.docx Signed ICC MoM for MR Introductionpdf_19-04-18_19.11.43.pdf Minutes of ICC Meeting 04052017_18-04-18_16.20.23.docx Minutes of ICC Meeting 16102017_18-04-18_16.19.46.docx Minutes of ICC Meeting Re introduction of IPV 2017_18-04-18_16.19.16.docx Reintroduction of IPV in DPRK immunization programme 2018 D_18-04-18_16.18.37.docx

Other documents

✓	Other documents (optional)	Final draft Operational Guidelines for MR SIA in DPRK_19-04-18_18.15.53.doc
	Please also provide other country documents to support the review of the applications, for example Health Facility Assessment Reports, Knowledge-Attitude-Practice surveys or other demand-related surveys, if available.	

Measles-rubella 1st and 2nd dose routine, with catch-up campaign

Vaccine and programmatic data

3.1.1 Choice of presentation and dates

For each type of support please specify start and end date, and preferred presentations.
Measles-rubella 1st and 2nd dose routine

Preferred presentation	MR, 10 doses/vial, Iyo
Is the presentation licensed or registered?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
2nd preferred presentation	MR, 5 doses/vial, Iyo
Is the presentation licensed or registered?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
Required date for vaccine and supplies to arrive	5 August 2019
Planned launch date	21 October 2019
Support requested until	2020

Measles-rubella catch-up campaign

Preferred presentation	MR, 10 doses/vial, Iyo
Is the presentation licensed or registered?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
2nd preferred presentation	MR, 5 doses/vial, Iyo
Is the presentation licensed or registered?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
Required date for vaccine and supplies to arrive	5 August 2019
Planned launch date	1 October 2019
Support requested until	2020

3.1.2 Vaccine presentation registration or licensing

If any of the selected presentations are not yet licensed or registered, please describe the duration of the registration or licensing procedure, whether the country's regulations allow the

expedited procedure for national registration of WHO-pre-qualified vaccines, and confirm whether the licensing procedure will be completed ahead of the introduction or campaign.

The WHO pre-qualified products are not required to be licensed.

3.1.3 Vaccine procurement

Gavi expects that most countries will procure vaccine and injection supplies through UNICEF or PAHO's Revolving Fund. Does the country request an alternative mechanism for procurement and delivery of vaccine supply (financed by the country or Gavi)?

Yes No

If you have answered yes, please attach the following in the document upload section: * A description of the mechanism, and the vaccines or commodities to be procured by the country through this mechanism. * A confirmation that vaccines will be procured from the WHO list of pre-qualified vaccines, indicating the specific vaccine from the list of pre-qualification. OR, for the procurement of locally-produced vaccines directly from a manufacturer which may not have been prequalified by WHO, a confirmation should be provided that the vaccines purchased comply with WHO's definition of quality vaccines, for which there are no unresolved quality problems reported to WHO, and for which compliance is assured by a fully functional National Regulatory Authority (NRA), as assessed by WHO in the countries where they are manufactured and where they are purchased.

Target Information

3.2.1 Targets for routine vaccination

Please describe the target age cohort for the MR 1st dose routine immunisation:

9 weeks months years

Please describe the target age cohort for the MR 2nd dose routine immunisation:

15 weeks months years

	2019	2020
Population in the target age cohort (#)	355,670	355,670
Target population to be vaccinated (first dose) (#)	355,670	355,670
Target population to be vaccinated (last dose) (#)	355,670	355,670

Estimated wastage rates for preferred presentation (%)	10	10
--	----	----

3.2.2 Targets for campaign vaccination

Gavi will only provide support to countries for Rubella Containing Vaccine catch-up campaign by providing doses of MR vaccine for a target population of males and females aged 9 months to 14 years (the exact range in the scope of 9 months to 14 years old will depend on MR in the country).

Gavi will always provide 100% of the doses needed to vaccinate the population in the target age cohort.

Please describe the target age cohort for the measles-rubella catch-up campaign: (from 9m-14y).

From	9	weeks <input type="checkbox"/>	months <input checked="" type="checkbox"/>	years <input type="checkbox"/>
------	---	--------------------------------	--	--------------------------------

To	14	weeks <input type="checkbox"/>	months <input type="checkbox"/>	years <input checked="" type="checkbox"/>
----	----	--------------------------------	---------------------------------	---

	2019	2020
Population in target age cohort (#)	6,725,957	
Target population to be vaccinated (first dose) (#)	6,725,957	
Estimated wastage rates for preferred presentation (%)	10	

Co-financing information

3.3.1 Vaccine and commodities prices

Price per dose (US\$) - Measles-rubella routine, 1st and 2nd dose

	2019	2020
10 doses/vial,lyo	0.64	0.64

Commodities Price (US\$) - Measles-rubella routine, 1st and 2nd dose (applies only to preferred presentation)

	2019	2020
--	------	------

AD syringes	0.04	0.04
Reconstitution syringes	0.04	0.04
Safety boxes	0.47	0.47
Freight cost as a % of device value	0.01	0.01

Price per dose (US\$) - Measles-rubella catch-up campaign

	2019	2020
10 doses/vial,lyo	0.64	0.64

Commodities Price (US\$) - Measles-rubella catch-up campaign (applies only to preferred presentation)

	2019	2020
AD syringes	0.04	0.04
Reconstitution syringes	0.04	0.04
Safety boxes	0.47	0.47
Freight cost as a % of device value	0.01	0.01

3.3.2 Country choice of co-financing amount per vaccine dose

The table below shows the estimated financial commitment for the procurement of vaccines and supplies for the country, and the portion of Gavi support

	2019	2020
Country co-financing share per dose (%)	46.88	46.88
Minimum Country co-financing per dose (US\$)	0.3	0.3
Country co-financing per dose (enter an amount equal or above minimum)(US\$)	0.3	0.3

3.3.3 Estimated values to be financed by the country and Gavi for the procurement of supply

Measles-rubella routine, 1st and 2nd dose

	2019	2020
Vaccine doses financed by Gavi (#)	540,500	432,400
Vaccine doses co-financed by Country (#)	446,500	357,200
AD syringes financed by Gavi (#)	999,700	782,500
AD syringes co-financed by Country (#)		
Reconstitution syringes financed by Gavi (#)	108,600	86,900
Reconstitution syringes co-financed by Country (#)		
Safety boxes financed by Gavi (#)	12,200	9,575
Safety boxes co-financed by Country (#)		
Freight charges financed by Gavi (\$)	15,058	12,008
Freight charges co-financed by Country (\$)	12,442	9,921

	2019	2020
Total value to be co-financed (US\$) Country	296,500	237,000
Total value to be financed (US\$) Gavi	409,500	327,000
Total value to be financed (US\$)	706,000	564,000

Measles-rubella catch-up campaign

	2019	2020
Vaccine doses financed by Gavi (#)	7,465,900	
AD syringes financed by Gavi (#)	7,398,600	
Reconstitution syringes financed by Gavi (#)	821,300	
Safety boxes financed by Gavi (#)	90,425	
Freight charges financed by Gavi (\$)	207,336	

	2019	2020
Total value to be financed (US\$) Gavi	5,329,000	
Total value to be financed (US\$)	5,329,000	

3.3.4 Estimated projection of the required domestic financing for the measles monovalent component of MCV1

Countries are required to domestically finance the first dose in their measles containing vaccine routine (MCV1) in order to be able to receive Gavi support for any measles/ measles-rubella programmes. Below is the estimated projection of the required domestic financing for MCV1, based on the information provided in the previous sections.

	2019	2020
Minimum number of doses financed from domestic resources	235,952	188,761
Country domestic funding (minimum)	151,008	120,807

3.3.5 Co-financing payment

Please indicate the process for ensuring that the co-financing payments are made in a timely manner.

The government has committed for the timely payment of the co-financing share. WHO and UNICEF country offices continuously monitor the situation and advise the government in case of default.

Following the regulations of the internal budgeting and financing cycles the Government will annually release its portion of the co-financing funds in the month of:

June

The payment for the first year of co-financed support will be made in the month of:

Month

June

Year

2019

Financial support from Gavi

3.4.1 Routine Vaccine Introduction Grant(s)

Measles-rubella 1st and 2nd dose routine
Live births (year of introduction)

362,670

Gavi contribution per live birth (US\$)

0.8

Total in (US\$)

290,136

Funding needed in
country by

31 December 2018

3.4.2 Campaign operational costs support grant(s)

Measles-rubella catch-up campaign
Population in the target age cohort (#)

6,725,957

Gavi contribution per person in the target age cohort (US\$)

0.65

Total in (US\$)

4,371,872.05

Funding needed in
country by

31 December 2018

3.4.3 Operational budget

Please complete the Gavi budgeting and planning template to document how the Gavi Vaccine Introduction Grant and the Campaign Operational Costs support grant will be used to facilitate the timely and effective implementation of critical activities in advance of and during the campaign and the introduction of the new vaccine. Please ensure to upload the completed budgeting and planning template as part of this application.

If Gavi's support is not enough to cover the full needs please indicate how much and who will be complementing the funds needed in the Operational Budget template. In the following fields please provide an overview of your request.

Total amount - Gov. Funding / Country Co-financing (US\$)

0

Total amount - Other donors (US\$)

0

Total amount - Gavi support (US\$)

4371872

Amount per target person - Gov. Funding / Country Co-financing (US\$)

0.65

Amount per target person - Other donors (US\$)

0

Amount per target person - Gavi support (US\$)

0.65

3.4.4 Financial management procedures

Please describe the financial management procedures that will be applied for the management of the NVS direct financial support, including any procurement to be incurred.

WHO and UNICEF standard financial management procedures

3.4.5 Fiduciary management

Please indicate whether funds for operational costs should be transferred to the government or WHO and/or UNICEF and when funding is expected to be needed in country. Attach banking form if funding should be transferred to the government. Please note that UNICEF and WHO will require administrative fees as follows.

- o UNICEF Tripartite Agreement: 5%
- o UNICEF Bilateral Agreement: 8%
- o WHO Bilateral Agreement: 7%.

Funds need to be transferred to WHO and UNICEF following the submitted budget.

3.4.6 Use of financial support to fund additional Technical Assistance needs

Gavi funds through its Partner Engagement Framework / TCA, tailored and differentiated technical assistance in response to specific country needs. Please review the currently approved technical assistance plan (also referred to as the “One TA plan”) with a view to assess that required support for the implementation of the new vaccine support is contained in the approved technical assistance plan. If gaps in technical assistance are identified for the new vaccine support, the additionally required technical assistance may be funded through the vaccine introduction grant or campaign operational costs support. In this case, the relevant costs must be reflected in the budgeting and planning template. In addition, please indicate the programmatic areas for additional technical assistance needs and the respective agencies providing the technical assistance (if already identified) below.

PEF TCA in 2019 will provide support for campaign preparedness activities, routine introduction, etc. Priorities will be discussed during the Joint Appraisal.

Strategic considerations

3.5.1 Rationale for this request

Describe the rationale for requesting these new programme(s), including the burden of disease. If already included in detail in the Vaccine Introduction Plan or Campaign Plan of Action, please cite the sections only.

The MR introduction in the country will help in building population immunity against rubella as well as Measles thereby reducing The disease burden and load on the health care delivery systems. the proposed introduction will also help the country in achieving the regional and global targets for measles elimination and rubella/CRS control. (for detailed rationale please refer to the proposal)

3.5.2 Alignment with country strategic multi-year plan / comprehensive multi-year plan (cMYP)

Please describe how the plans and key assumptions in this request align with the most recent country strategic multi-year plan (cMYP) and other national health and immunisation plans.

The MR introduction plan is in line with the comprehensive multiyear plan 2016-2020 (cMYP) as well as the five year National Strategic Plan on measles elimination and rubella/CRS control 2018-2023.

3.5.3 Coordination Forum (ICC, HSCC or equivalent) and technical advisory committee (NITAG)

Provide a description of the roles of the national Coordination Forum (ICC, HSCC or equivalent body) and national immunization technical advisory group (NITAG) in developing this request. If any of Gavi's requirements to ensure basic functionality of the relevant national Coordination Forum (ICC, HSCC or equivalent) were not met, please describe the reasons and the approach to address this. Requirements can be found in the general application guidelines. In the absence of a NITAG, countries should clarify the role and functioning of the advisory group and describe plans to establish a NITAG.

The NITAG provided the requisite technical inputs as well as coordination with the concerned technical units in the decision making and development of the proposal. The ICC reviewed the recommendations of the NITAG and partners and took the final decision of introduction of MR and submission of application for Gavi support in implementing the decision. The ICC further issued directions to all the line ministries and departments in preparation and implementation of MR introduction in DPRK.

3.5.4 Financial sustainability

Please discuss the financing-related implications of the new vaccine programs requested, particularly how the government intends to fund the additional co-financing obligations. Please mention if any defaults occurred in the last three years and, if so, describe any mitigation measures that have been implemented to avoid future defaults. Additionally has the country taken into account future transition from Gavi support?

The government, despite of the challenged financial situation, is fully committed to the health of its citizens. It has been fulfilling the co-financing requirements though there was a default for a short period in 2016. Partners regularly followed up the process and discussed the possible ways of support. DPRK is still in the initial self financing phase. There is no discussion on transition from Gavi support as per the Gavi projections at this stage.

3.5.5 Programmatic challenges

Summarise programmatic challenges that need to be addressed to successfully implement the requested vaccine support, and describe plans for addressing those. These may include plans to address the barriers identified in the coverage and equity situation analysis section, and include vaccine supply chain, demand generation/ community mobilisation, data quality/ availability/ use and leadership, management and coordination, etc.

DPRK has a structured functioning RI programme. However, there are challenges in ISCL, workforce capacity and updated knowledge and skills, vaccine hesitancy for pentavalent vaccine and quality of data. The proposal covers the areas identified through previous external reviews, surveys and evaluations and highlights how MR introduction will strengthen routine immunization.

3.5.6 Improving coverage and equity of routine immunisation

Explain how the proposed NVS support will be used to improve the coverage and equity of routine immunisation, by detailing the proposed activities and budget will contribute to overcoming key barriers.

The latest coverage evaluation survey is a clear evidence for equity in immunization where the interprovincial and intra-provincial variation remains less than 1%. However, the NVS support will enhance the capacity of the Immunization related HR at all levels and improve the quality of planning supplies and logistics as well.

3.5.7 Synergies

Describe potential synergies across planned introductions or campaigns. If relevant, comment on capacity and appropriate systems to introduce multiple vaccines in a year. Also describe how the country will mitigate any programmatic and financial risks associated with multiple introductions.

There are no two introductions planned for 2019.

3.5.8 Indicative major measles and rubella activities planned for the next 5 years

Summarise in one paragraph the indicative major measles and rubella activities planned for the next five years that are reflected in the annual EPI plan (e.g. measles second dose introduction, measles or measles-rubella follow up campaign, etc.).

- > Measles/Rubella SIAs followed by the routine introduction
 - > Case based Measles and Rubella/CRS surveillance
 - > Expansion of CRS surveillance
 - > Data quality improvement overall
- Please refer to the NSP 2018-2023 for details.

Report on Grant Performance Framework

3.6.1 Grant Performance Framework – Application Instructions

The Grant Performance Framework (GPF) contains all indicators that will be used to monitor programmatic performance for your requested type of support. Targets that were entered for number to be vaccinated in section 3 on the Target Information tab, have been carried over into their respective indicators in the GPF. Based on these numbers, coverage and dropout rate targets were calculated (where applicable). These appear as “calculated targets”. If you wish to revise these target values, please revise in the application form – they are not editable in the performance framework. In addition, as a part of your application, there are several items to be filled directly into the GPF. These are broken into required and optional items, below:

Required

1. In addition to the calculated targets, country targets are required to be submitted for outcome indicators. These targets should align to those in your cMYP or NHSP. If these targets are not in your cMYP or NHSP, or are the same as the calculated targets, please enter “NA” for each target value.
2. Additional indicators that appear in the Performance Framework that are not included in the application form. Please enter targets for these indicators.
3. For many indicators, reporting dates have been pre-populated. For those that have not yet been pre-populated, please add reporting dates.

Optional

1. Adding data sources to existing indicators: If there are data sources for indicators that you would like to include, you may add an additional source by clicking on the pencil icon next to the indicator name.
2. Adding new indicators: Gavi requires all countries to report on core indicators, which are already included in the GPF. If you wish to add supplemental indicators to monitor performance, you may do so by clicking the “Add indicator” button at the respective performance level (Outcome, Intermediate Result, or Process).

Please note that the GPF is filtered by default to only show indicators that are relevant to the specific types of support contained in the application. You may view the entire GPF by using the “Grant Status” filter. Please ensure your pop-up blocker is disabled when launching the GPF.

If you have any questions, please send an email to countryportal@gavi.org.

Upload new application documents

3.7.1 Upload new application documents

Below is the list of **application specific documents** that must be provided with your application.

In the case a document cannot be provided, please use the comment box to explain why, or by when it will be available.

Application documents

✓	New vaccine introduction plan (NVIP) and/or campaign plan of action (PoA), including checklist & activity list and timeline	DPRK New Vaccine Introduction Plan for measlesrubella _27-04-18_22.13.06.doc
	If support for a campaign and routine introduction is requested at the same time, the new vaccine introduction plan and campaign plan of action can be combined into one document to minimise duplication.	
✓	Gavi budgeting and planning template	Budgeting and Planning Pushpa Revised 26052018.xls_01-06-18_23.53.06.xlsx
✓	Most recent assessment of burden of relevant disease	DPRK Situation analysis measles rubella CRS _27-04-18_22.12.02.doc
	If not already included in detail in the Introduction Plan or Plan of Action.	
	Campaign target population (if applicable)	No file uploaded
		The population targets for the routine as well as SIAs have already been entered in the application and mandatory documents.

Endorsement by coordination and advisory groups

✓	National coordination forum meeting minutes, with endorsement of application, and including signatures	Signed ICC MoM for MR Introductionpdf_19-04-18_19.09.07.pdf
	The minutes of the national coordination forum meeting should mention the domestic funding of MCV1	



NITAG meeting minutes

with specific recommendations on the NVS introduction or campaign

NITAG MR introduction in DPRK immunization programme 2018_18-04-18_17.46.27.docx

Vaccine specific



cMYP addendum

Situation analysis and 5 year plan captured in the cMYP or as an addendum to the cMYP

Addendum for cMYP_27-04-18_22.52.09.docx



Annual EPI plan

Annual EPI plan detailing planning of all measles and rubella-related activities for the current year, including realistic timelines, designated responsible individual(s) and a budget

Copy of Matrix for EPI annual plan 2018DPRK_18-04-18_17.59.08.xlsx



Other documents (optional)

Annex 8. Field Guidelines for Vaccination Teams DPRK_01-06-18_23.49.56.doc

TOR NITAGE_01-06-18_23.50.29.docx

Annex 7. Framework for school immunization guidelines DPRK_01-06-18_23.49.35.doc

Operational Guidelines for MR SIA in DPRK_27-04-18_22.15.52.doc

Annex 6. RCM Form_01-06-18_23.49.11.xlsx

Annex 5. SIAReadinessAssessmentTool_01-06-18_23.48.50.xlsx

Annex 4. Intra campaign Supervisory checklist MR SIA 2019 DPRK_01-06-18_23.48.22.doc

[Annex3 Pre campaign Supervisory checklist MR SIA 2019 DPRK_01-06-18_23.47.56.doc](#)

[Annex 2 Frequently asked questions MR SIA in DPRK_01-06-18_23.47.36.doc](#)

[Annex.1 Timeline for MR SIAs DPRK_01-06-18_23.46.50.docx](#)

[DPRK National Plan of Action for MR SIA_01-06-18_23.45.45.doc](#)



MCV1 self-financing commitment letter

[Cofinancing commitment_20-04-18_16.35.34.pdf](#)

If the country is not yet financing the measles monovalent component of MCV1, a letter signed by the Minister of Health and Minister of Finance committing for the country to self-finance MCV1 from 2018 onwards.



Measles (and rubella) strategic plan for elimination

[DPRK National 5 y strategic Plan 2018 2022_27-04-18_22.14.01.doc](#)

Review and submit application

Submission Details

Country vaccine funding summary

Please review the estimated projections for new vaccine programmes included in this application.

Active Vaccine Programmes

IPV Routine

	2018	2019	2020	2021	2022
Country Co-financing (US\$)					
Gavi support (US\$)	754,000	819,568	819,568	819,307	818,089

Pentavalent Routine

	2018	2019	2020	2021	2022
Country Co-financing (US\$)	231,978	235,143	235,143	231,813	231,342
Gavi support (US\$)	1,122,000	1,102,500	1,102,500	1,077,305	1,075,115

Total Active Vaccine Programmes

	2018	2019	2020	2021	2022
Total country co-financing (US\$)	231,978	235,143	235,143	231,813	231,342
Total Gavi support (US\$)	1,876,000	1,922,068	1,922,068	1,896,612	1,893,204
Total value (US\$) (Gavi + Country co-financing)	2,107,978	2,157,211	2,157,211	2,128,425	2,124,546

New vaccine support requested

Measles-rubella 1st and 2nd dose routine, with catch-up campaign

	2019	2020
Country Co-financing (US\$)	296,500	237,000
Gavi support (US\$)	5,738,500	327,000

	2019	2020
Total country co-financing (US\$)	296,500	237,000
Total Gavi support (US\$)	5,738,500	327,000
Total value (US\$) (Gavi + Country co-financing)	6,035,000	564,000

Total Portfolio Overview – Existing Programs + New Vaccine Support Requested (US\$)

	2018	2019	2020	2021	2022
Total country co-financing (US\$)	231,978	531,643	472,143	231,813	231,342
Total Gavi support (US\$)	1,876,000	7,660,568	2,249,068	1,896,612	1,893,204
Total value (US\$) (Gavi + Country co-financing)	2,107,978	8,192,211	2,721,211	2,128,425	2,124,546

Contacts

Person(s) who should be contacted in case Gavi needs to ask for more information in regard to the application.

Name	Position	Phone Number	Email	Organisation
Wijesinghe Pushpa Ranjan	Medical Officer	191 250 0582	wijesinghep@who.int	
Muhammad Tariq Iqbal	Health Specialist	191 250 7077	mtiqbal@unicef.org	

Please let us know if you have any comments about this application

There seems to be duplication of the information requested at many places. It would be wonderful if each country portal would have all the basic information uploaded for once and then it can be updated periodically.

Government signature form

The Government of Democratic People's Republic of Korea would like to expand the existing partnership with Gavi for the improvement of the immunisation programme of the country, and specifically hereby requests Gavi support for:

Measles-rubella 1st and 2nd dose routine, with catch-up campaign

The Government of Democratic People's Republic of Korea commits itself to developing national immunisation services on a sustainable basis in accordance with the national health and immunisation strategic plans. The Government requests that Gavi and its partners contribute financial and technical assistance to support immunisation of children as outlined in this application.

The co-financing commitments in this application include the amount of support in either supplies or cash that is requested from Gavi, and the financial commitment of the Government for the procurement of this new vaccine.

Please note that Gavi will not review this application without the signatures of both the Minister of Health and Minister of Finance (and Minister of Education, if applicable) or their delegated authority.

We, the undersigned, affirm that the objectives and activities in this request are fully aligned with the national health and immunisation strategic plans (or equivalent), and that funds for implementing all activities, including domestic funds and any needed vaccine co-financing will be included in the annual budget of the Ministry of Health.

We, the undersigned, further affirm that the requested funding for salaries, salary top-ups/allowances, per diems and incentives does not duplicate funding from other sources (e.g. from other donors).

We, the undersigned, further affirm that the terms and conditions of the Partnership Framework Agreement between Gavi and the Country remain in full effect and shall apply to any and all Gavi support made pursuant to this application.¹

Minister of Health (or delegated authority)

Name

Date

Signature

Minister of Finance (or delegated authority)

Name

Date

Signature

For countries requesting HPV support, with a school linked strategy, the signature of the Minister of Education (or delegated authority) is also required.

Minister of Education (or delegated authority)

Name

Date

Signature

¹ In the event the Country has not yet executed a Partnership Framework Agreement, the terms and conditions of this application shall apply to any and all Gavi support made pursuant to this application.